Testing an SGLT2 diabetes drug for depression
Treatments studied
Part of Mental health clinical trials.
This Phase 2 trial tests whether an SGLT2 medicine (like empagliflozin) can reduce symptoms of major depression. It may help people with moderate-to-severe depression who are otherwise eligible for the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old
- Have a current major depressive disorder diagnosis confirmed by a short interview
- Have depression that is at least moderate (MADRS score of 20 or higher)
- Not have bipolar or other psychotic disorders (like schizophrenia) as a main diagnosis
- Not have previously taken an SGLT2 medicine, like empagliflozin
- Have no major kidney or liver problems, and meet study lab thresholds (GFR 45 or higher; A1c 8.0% or lower)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if empagliflozin (a diabetes drug) can help improve depression symptoms in people with bipolar disorder who also have insulin resistance. You take it alongside your current bipolar medications.
This trial tests whether dapagliflozin, a diabetes medication, can help treat major depression. It is for adults who have been depressed for at least 2 months and score high on a depression scale.
This trial tests if empagliflozin, a medication typically used for diabetes, can help people with metabolic syndrome (a cluster of conditions like large waist size, high blood sugar, and high blood pressure). It may improve health and reduce the risk of heart disease.
This study tests if a type 2 diabetes medication (SGLT2 inhibitor) can help people with frequent gout flares. It aims to lower uric acid levels and reduce flare-ups.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This trial tests a medication called empagliflozin (a type 2 diabetes pill) to see how well it works in people with type 2 diabetes who have not taken any diabetes drugs for at least 8 weeks. If you qualify, you may receive the study drug and help researchers learn more about managing blood sugar.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.